Synthesis of leukotriene B4 antagonists labeled with In-111 or Tc-99m to image infectious and inflammatory foci

Journal of Medicinal Chemistry

Volumn 48, Issue 20, 2005, Pages 6442-6453

  Broekema, Matthias ^a,b   Van Eerd, Julliëtte J E M ^c   Oyen, Wim J G ^c   Corstens, Frans H M ^c   Liskamp, Rob M J ^b   Boerman, Otto C ^c   Harris, Thomas D ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b UTRECHT UNIVERSITY   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 57868 81; BMS 57868 88; CHELATING AGENT; DPC 11870 11; HYDRAZINONICOTINIC ACID; INDIUM 111; ISONICOTINIC ACID; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LIGAND; PENTETIC ACID; TECHNETIUM 99M; TRICINE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG CONJUGATION; ESCHERICHIA COLI; GRANULOCYTE; HUMAN; HUMAN CELL; INFECTION; INFLAMMATION; ISOTOPE LABELING; NONHUMAN; RABBIT; RECEPTOR BINDING; SCINTIGRAPHY; SCINTILLATION CAMERA;

ABSCESS; ANIMALS; BINDING, COMPETITIVE; CHELATING AGENTS; ESCHERICHIA COLI INFECTIONS; FEMALE; GLYCINE; GRANULOCYTES; HUMANS; HYDRAZINES; INDIUM RADIOISOTOPES; ISONICOTINIC ACIDS; ISOTOPE LABELING; LEUKOTRIENE B4; MUSCLE, SKELETAL; NICOTINIC ACIDS; ORGANOTECHNETIUM COMPOUNDS; RABBITS; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 26444534425     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050383h     Document Type: Article

References (34)

1. 4 receptors. Prostaglandins Leukot. Essent. Fatty Acids 2003, 69, 123-134.
2. 4 that mediates chemotaxis. Nature 1997, 387, 620-624.
3. 4 receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J. Exp. Med. 2000, 192, 421-432.
4. 4 receptors. Prostaglandins Other Lipid Mediat. 2002, 68-69, 575-585.
5. 4 and inflammatory disease. Agents Actions 1988, 24, 114-119.
6. Brooks, C. D.; Summers, J. B. Modulators of Leukotriene Biosynthesis and Receptor Activation. J. Med. Chem. 1996, 39, 2629-2654.
7. van Eerd, J. E.; Boerman, O. C.; Corstens, F. H.; Oyen, W. J. Radiolabeled chemotactic cytokines: new agents for scintigraphic imaging of infection and inflammation. Q. J. Nucl. Med. 2003, 47, 246-255.
8. Bleeker-Rovers, C. P.; Boerman, O. C.; Rennen, H. J.; Corstens, F. H.; Oyen, W. J. Radiolabeled compounds in diagnosis of infectious and inflammatory disease. Curr. Pharm. Des. 2004, 10, 2935-2950
9. 4 antagonist as potential infection/inflammation imaging agents. Abstracts of Papers, 216th National Meeting of the American Chemical Society, Boston, MA, Aug 23-27, 1998; American Chemical Society: Washington, DC, 1998; U211-U211 035.
10. 4 Antagonists. J. Med. Chem. 1992, 35, 4315-4324.
11. 99mTc- Labeled Radiopharmaceuticals. Bioconjugate Chem. 1999, 10, 808-814.
12. 99mTc. Bioconjugate Chem. 1997, 8, 146-154.
13. 4 receptor antagonist for scintigraphic detection of infection in rabbits. Nucl. Med. Commun. 2000, 21, 1043-1050.
14. 4) antagonist for scintigraphic imaging of infectious foci. J. Nucl. Med. 2003, 44, 1087-1091
15. Isida, T.; Akiyama, T.; Nabika, K.; Sisido, K.; Kozima, S. The Formation of Tin-Nitrogen Bonds. V. The Selective 1-Substitution Reaction of Tetrazoles by the Reaction of 5-substituted 2-(Tri-n-butylstannyl)tetrazoles with Methyl Iodide, Methyl p-Toluenesulfonate, Dimethyl Sulfate, and Ethyl Bromoacetate. Bull. Chem. Soc. Jpn., 1973, 46, 2176-2180.
16. Edwards, D. S.; Liu, S.; Ziegler, M. C.; Harris, A. R.; Crocker, A. C.; Heminway, S. J.; Barrett, J. A.; Bridger, G. J.; Abrams, M. J.; Higgins, J. D. 3rd. RP463: a stabilized technetium-99m complex of a hydrazino nicotinamide derivatized chemotactic peptide for infection imaging. Bioconjugate Chem. 1999, 884-91.
17. 4 receptor antagonists: A most discriminating class of antiinflammatory agent? Drugs Future. 1992, 17, 819-830.
18. 4 antagonists. Curr. Drugs 1994, 13-22.
19. Lin, K. S.; Luu, A.; Baidoo, K. E.; Hashemzadeh-Gargari, H.; Chen, M. K.; Brenneman, K.; Pili, R.; Pomper, M.; Carducci, M. A.; Wagner, H. N., Jr. A New High Affinity Technetium-99m-Bombesin Analogue with Low Abdominal Accumulation. Bioconjugate Chem. 2005, 16, 43-50.
20. 125I-labeled RGD peptide are improved by PEGylation. Nucl. Med. Biol. 2004, 3, 11-9.
21. 99mTc-labeled peptides. Q. J. Nucl. Med. 2002, 46, 195-205. Review.
22. Rennen, H. J.; van Eerd, J. E.; Oyen, W. J.; Corstens, F. H.; Edwards, D. S.; Boerman, O. C. Effects of coligand variation on the in vivo characteristics of Tc-99m-labeled interleukin-8 in detection of infection. Bioconjugate Chem. 2002, 13, 370-377.
23. Su, Z.; He, J.; Rusckowski, M.; Hnatowich, D. J. In Vitro Cell Studies of Technetium-99m Labeled RGD-HYNIC Peptide, A Comparison of Tricine and EDDA as Co-Ligands. Nuc. Med. Biol. 2003, 30, 141-149.
24. Barrett, J. A.; Cheesman, E. H.; Harris, T. D.; Rajopadhye, M. Radiopharmaceuticals for Imaging Infection and Inflammation. U.S. Patent 6,416,733, 2002.
25. Butler, R. N. Recent advances in tetrazole chemistry. Adv. Heterocycl. Chem. 1977, 21, 323-435.
26. Mammen, M.; Choi, S.; Whitesides, G. M. Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. Angew. Chem., Int. Ed. 1998, 37, 2754-2794.
27. Janssen, M.; Oyen, W. J.; Massuger, L. F.; Frielink, C.; Dijkgraaf, I.; Edwards, D. S.; Radjopadhye, M.; Corstens, F. H.; Boerman, O. C. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother. Radiopharm. 2002, 17, 641-646.
28. 99mTc Using Aminocarboxylates as Coligands. Bioconjugate Chem. 1996, 7, 63-71.
29. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor- positive tumors: preclinical evaluation and comparison with 111In-octreotide. J. Nucl. Med. 2000, 41, 1114-9.
30. Hubbuch, A.; Danho, W.; Zahn, H. Synthesis of N-Protected Cysteic Acid Derivatives and Their Activated Esters. Liebigs Ann. Chem. 1979, 776-783.
31. Harris, T. D.; Barrett, J. A.; Carpenter, A. P.; Rajopadhye, M. Vitronectin receptor antagonist pharmaceuticals. U.S. Patent 6,511,649, B1, 2003.
32. Schwartz, D. A.; Abrams, M. J.; Giademenico, C. M.; Zubieta, J. A. Certain Pyridyl Hydrazines and Hydrazides Useful for Protein Labeling. U.S. Patent 5,206,370, 1993.
33. Wilbur, D. S.; Hamlin, D. K.; Buhler, K. R.; Pathare, P. M.; Vessella, R. L.; Stayton, P. S.; To, R. Streptavidin in Antibody Pretargeting. 2. Evaluation of Methods for Decreasing Localization of Streptavidin to Kidney while Retaining Its Tumor Binding Capacity. Bioconjugate Chem. 1998, 9, 322-330.
34. van der Laken, C. J.; Boerman, O. C.; Oyen, W. J.; van de Ven, M. T.; Edwards, D. S.; Barrett, J. A.; van der Meer, J. W.; Corstens, F. H. Technetium-99m-labeled chemotactic peptides in acute infection and sterile inflammation. J Nucl. Med. 1997, 38, 1310-1315.